Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

141.95 +2.01 (+1.44%)
Streaming Delayed Price Updated: 10:50 AM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
54 55 Next >
Tuesday Talk: CPI Data And FOMC Meeting Hold Back Market Breakout
While the market continues towards making new highs, it is falling short of making a breakout rally. Forthcoming CPI data and the upcoming FOMC meeting may be the catalyst for same. 
Via Talk Markets
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,200 Today
 
Via Benzinga
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond
These stocks aren't worth the risk. 
Via The Motley Fool
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%). 
Via Benzinga
Topics Stocks
The Latest Analyst Ratings for Biogen
 
Via Benzinga
Why This Biogen Analyst Is Turning Bullish On Alzheimer's Treatment Prospects
Biogen Inc (NASDAQ: BIIB) has been in focus due to its treatment for early-stage Alzheimer’s disease. 
Via Benzinga
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. 
Via MarketBeat
Topics Bonds
Comparative Study: Biogen And Industry Competitors In Biotechnology Industry
 
Via Benzinga
Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today
 
Via Benzinga
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry
 
Via Benzinga
Expert Ratings for Biogen
 
Via Benzinga
Looking Into Biogen's Recent Short Interest
 
Via Benzinga
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this  
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Biotech companies are edging closer to finding the answers behind Alzheimer's disease. 
Via Investor's Business Daily
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years
 
Via Benzinga
Assessing Biogen's Performance Against Competitors In Biotechnology Industry
 
Via Benzinga
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
The real competitive battle is about to begin, and it will last a long time. 
Via The Motley Fool
These Analysts Revise Their Forecasts On Biogen After Q3 Results
Biogen Inc (NASDAQ: BIIB) reported better-than-expected third-quarter earnings. 
Via Benzinga
Thoughts For Thursday: Staying On Top - Barely
The stock market continues to be full of worry, but is managing to stay on top this week, so far. It is worth noting that yesterday's close brought levels back to those of a month ago. 
Via Talk Markets
Biogen (BIIB) Q3 2023 Earnings Call Transcript
BIIB earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides
Biogen Inc (NASDAQ: BIIB) posted Q3 FY23 sales of $2.53 billion, beating the con 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Compared To Estimates, Biogen Inc. Q3 Earnings: A Look At Key Metrics
Biogen Inc. reported $2.53 billion in revenue for the quarter ended September 2023. 
Via Talk Markets
US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings
Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reserve Chair Jerome Powell’s speech for insights into... 
Via Benzinga
Topics Economy
Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount
The company shares in the profits and sales related to Alzheimer's treatment, Leqembi. 
Via Investor's Business Daily
3 Biotech Moonshots to Bet on the Future of Health
Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk. 
Via InvestorPlace
Topics Intellectual Property
Biogen Appoints Monish Patolawala to its Board of Directors
Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformation 
From Biogen Inc.
Via GlobeNewswire
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment
Both companies are working on under-the-skin injections for Alzheimer's treatment. 
Via Investor's Business Daily
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.